Skip to main content
SpringerLink
Log in

Restless Legs Syndrome in the Older Adult

Diagnosis and Management

  • Therapy in Practice
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Restless legs syndrome (RLS) is common in the elderly, with an estimated prevalence of 10 to 35% in individuals over 65 years of age. RLS is characterised by paraesthesias and dysaesthesias of the legs, typically occurring in the evening. The symptoms occur at rest and result in motor restlessness; movement often temporarily relieves the symptoms. Patients with poorly controlled RLS may develop related problems including insomnia (due to sleep-onset restlessness or periodic limb movements or related sleep fragmentation) and depression. RLS can be a primary disorder that develops in the young and includes familial cases. Secondary RLS occurs in association with iron-deficiency anaemia, uraemia and polyneuropathies. Typically, RLS is misdiagnosed or undiagnosed for years. In the elderly, both primary and secondary types of the disorder are common.

It is thought that RLS represents lower CNS levels of, or reduced responsiveness to, dopamine. The symptoms improve with dopaminergic therapy. Ergotamine dopamine-receptor agonists such as pergolide, and the non-ergotamine dopamine-receptor agonists pramipexole and ropinirole, are becoming more commonly used to treat RLS. The dopamine precursor levodopa, in combination with carbidopa, is another effective therapeutic agent. An advantage of levodopa is lower cost than non-ergotamine and ergotamine dopamine-receptor agonists. However, the adverse effect of symptom augmentation appears to develop more frequently with levodopa than dopamine-receptor agonists; therefore, levodopa may currently be used somewhat less often as first-line therapy. Patients with painful symptoms may respond favourably to the anticonvulsants gabapentin and carbamazepine. Opioids and hypnosedatives are helpful in selected patients; however, these agents may have troubling adverse effects in the elderly. Correction of iron deficiency improves symptoms in patients with low ferritin levels. Lifestyle modification may also be helpful. Therapy is directed at symptoms, and most symptomatic patients benefit from treatment. It is important to consider RLS in the differential diagnosis of any patient with paraesthesias of the limbs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II

Similar content being viewed by others

References

  1. American Sleep Disorders Association. Restless legs syndrome. International classification of sleep disorders, revised: diagnostic and coding manual. Rochester (MN): American Sleep Disorders Association, 1997: 68–71

    Google Scholar 

  2. Walters AS, Hickey K, Maltzman J, et al. A questionnaire study of 138 patients with restless legs syndrome: the nightwalkers survey. Neurology 1996; 46: 92–5

    Article  PubMed  CAS  Google Scholar 

  3. Trenkwalder C, Walters AS, Hening W. Periodic limb movements and restless legs syndrome. Neurol Clin 1996; 14: 629–50

    Article  PubMed  CAS  Google Scholar 

  4. Ekbom KA. Restless legs syndrome. Neurology 1960; 10: 868–73

    Article  PubMed  CAS  Google Scholar 

  5. Walters AS. Toward a better definition of the restless legs syndrome. Mov Disord 1995; 5: 634–42

    Article  Google Scholar 

  6. Ondo W, Jankovic J. Restless legs syndrome: clinicoetiologic correlates. Neurology 1996; 47: 1435–41

    Article  PubMed  CAS  Google Scholar 

  7. Allen RP, Earley CJ. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol 2001; 18: 128–47

    Article  PubMed  CAS  Google Scholar 

  8. Rothdach AJ, Trenkwalder C, Haberstock J, et al. Prevalence and risk factors of RLS in an elderly population. Neurology 2000; 54: 1064–8

    Article  PubMed  CAS  Google Scholar 

  9. Montplaisir J, Nicolas A, Godbout R, et al. Restless legs syndrome and periodic limb movement disorder. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 3rd ed. Philadelphia (PA): WB Saunders, 2000: 742–52

    Google Scholar 

  10. Allen RP, Earley CJ. Defining the phenotype of the restless legs syndrome using age-of-symptom-onset. Sleep Med 2000; 1: 11–9

    Article  PubMed  Google Scholar 

  11. Sun ER, Chen CA, Ho G, et al. Iron and the restless legs syndrome. Sleep 1998; 21: 371–7

    PubMed  CAS  Google Scholar 

  12. Schols L, Haan J, Riess O, et al. Sleep disturbance in spinocerebellar ataxias. Neurology 1998; 51: 1603–7

    Article  PubMed  CAS  Google Scholar 

  13. Chesson AL, Wise M, Davila D, et al. Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. Sleep 1999; 22: 961–8

    PubMed  Google Scholar 

  14. Henning W, Allen R, Earley C, et al. The treatment of restless legs syndrome and periodic limb movement disorder. Sleep 1999; 22: 970–99

    Google Scholar 

  15. Henning WA. Restless legs syndrome. Curr Treat Options Neurol 1999; 1: 309–19

    Article  Google Scholar 

  16. Restless Legs Syndrome Foundation, Inc. Medical Bulletin (revised April 2001). Rochester (MN): The Foundation, 2001

    Google Scholar 

  17. O’Keeffe ST, Gavin K, Lavan JN. Iron status and restless legs syndrome in the elderly. Age Ageing 1994; 23: 200–3

    Article  PubMed  Google Scholar 

  18. Davis BJ, Rajput A, Rajput ML, et al. A randomized, double blind placebo controlled trial of iron in restless legs syndrome. Eur Neurol 2000; 43: 70–5

    Article  PubMed  CAS  Google Scholar 

  19. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996; 19: 205–13

    PubMed  CAS  Google Scholar 

  20. Poewe W, Hogl B. Parkinson’s disease and sleep. Curr Opin Neurol 2000; 13: 423–6

    Article  PubMed  CAS  Google Scholar 

  21. Stiasny K, Wetter TC, Winkelmann J, et al. Long-term effects of pergolide in the treatment of restless legs syndrome. Neurology 2001; 56: 1399–402

    Article  PubMed  CAS  Google Scholar 

  22. Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson’s disease patients with treatment-induced hallucinations. Ann Neurol 1993; 34(5): 710–4

    Article  PubMed  CAS  Google Scholar 

  23. Danoff SK, Grasso ME, Terry PB, et al. Pleuropulmonary disease due to pergolide use for restless legs syndrome. Chest 2001; 120(1): 313–6

    Article  PubMed  CAS  Google Scholar 

  24. O’Keefe ST. Restless legs syndrome: a review. Arch Intern Med 1996; 156(3): 243–8

    Article  Google Scholar 

  25. Becker PM, Jamieson AO, Brown WD. Dopaminergic agents in restless legs syndrome and periodic limb movements of sleep: response and complications of extended treatment in 49 cases. Sleep 1993; 16(8): 713–6

    PubMed  CAS  Google Scholar 

  26. Montplaisir J, Nicolas A, Denesle R, et al. Restless legs syndrome improved by pramipexole. Neurology 1999; 52: 938–43

    Article  PubMed  CAS  Google Scholar 

  27. Montplaisir J, Denesle R, Petit D. Pramipexole in the treatment of restless legs syndrome: a follow-up study. Eur J Neurol 2000; 7(Suppl. 1): 27–31

    Article  PubMed  Google Scholar 

  28. Weimerskirch PR, Ernst ME. Newer dopamine agonists in the treatment of restless legs syndrome. Ann Pharmacother 2001; 35: 627–30

    Article  PubMed  CAS  Google Scholar 

  29. Frucht S, Rogers JD, Greene PE, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52: 1908–10

    Article  PubMed  CAS  Google Scholar 

  30. Ondo W. Ropinirole for restless lsegs syndrome. Mov Disord 1999; 14(1): 138–40

    Article  PubMed  CAS  Google Scholar 

  31. Olanow CW, Schapira AHV, Roth T. Waking up to sleep episodes in Parkinson’s disease. Mov Disord 2000; 15: 212–5

    Article  PubMed  CAS  Google Scholar 

  32. Ferreira JJ, Rascol O. Drug-related sleep disturbances and Parkinson’s disease: effect of dopaminergic antiparkinsonian drugs on sleep and wakefulness. Eur J Neurol 2000; 7Suppl. 4: 26–35

    Google Scholar 

  33. Happe S, Klosch G, Saletu B, et al. Treatment of idiopathic restless legs syndrome (RLS) with gabapentin. Neurology 2001; 57: 1717–9

    Article  PubMed  CAS  Google Scholar 

  34. Thorp ML, Morris CD, Bagby SP. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis 2001; 38: 104–8

    Article  PubMed  CAS  Google Scholar 

  35. Allen RP, Earley CJ. Validation of the Johns Hopkins Restless Legs Severity Scale. Sleep Med 2001; 2: 239–42

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank Patricia Fortenberry for her patient assistance with the preparation of this manuscript. No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

  1. Department of Medicine, Veterans Administration Medical Center and Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA

    Shawn A. Milligan &  Andrew L. Chesson Jr

Authors
  1. Shawn A. Milligan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew L. Chesson Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Milligan, S.A., Chesson, A.L. Restless Legs Syndrome in the Older Adult. Drugs Aging 19, 741–751 (2002). https://doi.org/10.2165/00002512-200219100-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200219100-00003

Keywords

Search

Navigation